Ann: Imugene to Present at Annual JPMorgan Healthcare Conference, page-33

lots of activity already it would seem:

• Novartis close to acquiring Cytokinetics after biotech's PhIII heart disease win — WSJ
• Novartis to acquire Calypso Biotech for autoimmune treatment
• J&J makes $2B push into ADCs with Ambrx buyout in oncology deal spree: #JPM24
• Veracyte to buy C2i Genomics for up to $95M, includes $70M upfront
• Alphabet's Isomorphic inks first pharma deals with Eli Lilly and Novartis for $83M upfront, $2.9B in milestones
• Merck brings Harpoon Therapeutics and its PhI/II T cell engager into the fold for $680M: #JPM24
• Novartis strikes $250M buyout for Merck Serono spinout's autoimmune 'pipeline-in-a-drug': #JPM24
• Novartis licenses two cardiovascular RNAi drugs from Chinese biotech for $185M upfront: #JPM24

#JPM24 on X (Twitter)

GLTAH!